Investigating Hematological and Renal Effects of Levetiracetam Versus Lamotrigine in Children With Epilepsy: A Randomized Clinical Trial

Objectives: Alterations in hematological and renal parameters have been reported with antiepileptic drugs. This study evaluates the effects of lamotrigine (LTG) and levetiracetam (LEV) on these parameters in children with epilepsy. Methods: This randomized clinical trial included children with a first-time diagnosis of epilepsy referred to Bandar Abbas Children’s Hospital, Bandar Abbas, Iran, from ۲۰۱۷ to ۲۰۱۸. The participants’ age, gender, and family history of epilepsy were recorded. The patients in the LTG group received ۰.۶ mg/kg oral LTG in two divided doses for two weeks which continued with ۱.۲ mg/kg for another two weeks and then with a maintenance dose of ۵-۱۵ mg/kg daily. The patients in the LEV group received ۱۰ mg/kg oral LEV twice a day. When necessary, the dosage is increased to a maximum of ۳۰ mg/kg twice a day. The treatment continued until seizures were controlled. Hematological and renal parameters were measured at baseline and ۳ months after treatment. The total duration of treatment with each drug was also noted. Results: From the ۶۶ children evaluated in this study with a mean age of ۸.۵۱±۲.۱۱ years, ۳۱ (۴۷%) were male. Age, gender, family history of epilepsy, treatment duration, and baseline hematological and renal parameters did not differ between the LTG group (n=۲۶) and the LEV group (n=۴۰). The patients in both groups were comparable in terms of all the parameters after treatment. Also, no significant change was observed after treatment compared to baseline in either group.  Discussion: LTG and LEV have no significant effect on the hematological and renal parameters of children with epilepsy.

کلیدواژه ها:

Epilepsy ، Lamotrigine ، Levetiracetam ، Blood ، Kidney